Molecular techniques, such as next-generation sequencing (NGS), are becoming more widely used to detect gene mutations, fusions, and other alterations that are characteristic of certain rare cancers [i.e., the CRTC1/MAML2 fusion transcript, which arises from the CRTC1/MAML2 translocation, is a major oncogenic driver for mucoepidermoid carcinoma (MEC)]. Here, CRTC1 is linked to mucoepidermoid carcinoma.